CD34 and angina pectoris: Most recently, Henry et al. demonstrated that autologous G-CSF mobilized CD34+ cells improves coronary flow reserve, CCS class, and life quality (based on the Seattle Angina Questionnaire (SAQ)) and mitigates angina frequency at 6 months after treatment (Henry et al., 2022).